TY - JOUR
T1 - Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression
AU - Hoover, Donald R.
AU - Peng, Yun
AU - Saah, Alfred
AU - Semba, Richard
AU - Detels, Roger R.
AU - Rinaldo, Charles R.
AU - Phair, John P.
PY - 1996/7
Y1 - 1996/7
N2 - Objective: To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 disease. Design: Cohort study. Setting: The Multicenter AIDS Cohort Study, an ongoing 10-year study of human immunodeficiency virus type 1-infected homosexual men with semiannual visits and CD4+ cell testing. Study Participants: Three hundred sixty-seven human immunodeficiency virus type 1-infected men from the Multicenter AIDS Cohort Study who were receiving zidovudine and Pneumocystis carinii prophylaxis and who had CD4+ cell counts fall below 0.10x109/L (100/μL). Main Outcome Measures: Kaplan-Meier-type estimates for various longitudinal quantifications of incidence and prevalence of CMV-R were obtained. Results: Among these 367 individuals, cytomegalovirus disease developed in 103, of whom 73 (71%) had ocular complications. At 4 years after the first CD4 cell count (<0.10x109/L), the probability for these subjects to have (1) remained living without CMV-R was 11%, (2) died without experiencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, and (4) experienced CMV-R and died was 18%. During these 4 years, there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R developed, about 19% did have CMV-R before a CD4+ cell count of less than 0.05x109/L (<50/μL) was observed, and 81% had CMV-R after the CD4+ cell count reached this threshold. Conclusion: These estimates may be relevant to current clinical practice and help in allocating resources and planning for treatment and prophylaxis against cytomegalovirus disease.
AB - Objective: To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 disease. Design: Cohort study. Setting: The Multicenter AIDS Cohort Study, an ongoing 10-year study of human immunodeficiency virus type 1-infected homosexual men with semiannual visits and CD4+ cell testing. Study Participants: Three hundred sixty-seven human immunodeficiency virus type 1-infected men from the Multicenter AIDS Cohort Study who were receiving zidovudine and Pneumocystis carinii prophylaxis and who had CD4+ cell counts fall below 0.10x109/L (100/μL). Main Outcome Measures: Kaplan-Meier-type estimates for various longitudinal quantifications of incidence and prevalence of CMV-R were obtained. Results: Among these 367 individuals, cytomegalovirus disease developed in 103, of whom 73 (71%) had ocular complications. At 4 years after the first CD4 cell count (<0.10x109/L), the probability for these subjects to have (1) remained living without CMV-R was 11%, (2) died without experiencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, and (4) experienced CMV-R and died was 18%. During these 4 years, there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R developed, about 19% did have CMV-R before a CD4+ cell count of less than 0.05x109/L (<50/μL) was observed, and 81% had CMV-R after the CD4+ cell count reached this threshold. Conclusion: These estimates may be relevant to current clinical practice and help in allocating resources and planning for treatment and prophylaxis against cytomegalovirus disease.
UR - http://www.scopus.com/inward/record.url?scp=0029946744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029946744&partnerID=8YFLogxK
U2 - 10.1001/archopht.1996.01100140035004
DO - 10.1001/archopht.1996.01100140035004
M3 - Article
C2 - 8660165
AN - SCOPUS:0029946744
SN - 0003-9950
VL - 114
SP - 821
EP - 827
JO - Archives of ophthalmology
JF - Archives of ophthalmology
IS - 7
ER -